VPC NeuroTherapeutics Inc.
VPC NeuroTherapeutics Inc. is a Canadian biotechnology company focused on developing and commercializing neuroprotective and anti-neuroinflammatory therapies for severe inflammatory diseases initiated by neurotrauma and stroke, such as spinal cord injury, traumatic brain injury, and concussion. The company leverages more than 35 years of research in neuropathology and preclinical models, translating these discoveries into novel clinical solutions. Its lead drug candidate, an oral formulation containing xanthohumol, has demonstrated efficacy in both preclinical and early clinical human studies. The company's multidisciplinary team encompasses clinical research, regulatory affairs, manufacturing, toxicology, and business development, working towards regulatory approvals, clinical trials, and eventual market access for its therapeutic innovations.
Industries
N/A
VPC NeuroTherapeutics Inc.
Hamilton, Ontario, Canada
Products
An oral small-molecule therapy containing xanthohumol for treatment of acute neuroinflammatory conditions such as spinal cord injury, traumatic brain injury, concussion, and stroke.
Development of an orally administered grain protein supplement with neuroprotective anti-inflammatory activity for use in aging or ailing brain conditions.
An oral small-molecule therapy containing xanthohumol for treatment of acute neuroinflammatory conditions such as spinal cord injury, traumatic brain injury, concussion, and stroke.
Development of an orally administered grain protein supplement with neuroprotective anti-inflammatory activity for use in aging or ailing brain conditions.
Services
Custom studies, including animal modeling, drug dosing, and preclinical evaluation of neuroprotective therapies.
Custom studies, including animal modeling, drug dosing, and preclinical evaluation of neuroprotective therapies.
Expertise Areas
- Neuroinflammation and neuroprotection
- Spinal cord injury research and therapy
- Translational medicine
- Preclinical model development
Key Technologies
- Oral small molecule CNS therapeutics
- Blood-brain barrier permeation studies
- Rat model of spinal cord injury
- MRI-based evaluation of neuroinflammation
Key People
President, CEO, CSO
Clinical Advisor
Investor Relations
Regulatory Affairs
Toxicology
Manufacturing
President, CEO, CSO
Clinical Advisor
Investor Relations
Regulatory Affairs
Toxicology
Manufacturing
News & Updates
Manuscript submission demonstrating anti-inflammatory effects in a spinal cord injury rat model.
Presentation by Jacek M. Kwiecien, DVM, MSc, PhD, on a grain protein with anti-neuroinflammatory activity for better function in aging brain.
Patent granted in the United States for use of anti-inflammatory agents for treatment of inflammation after neurotrauma and related diseases.
USPTO Patent US20220395474A1 for treatment of inflammation in central nervous system diseases including the use of oral xanthohumol.
USPTO application regarding further treatment approaches.
International PCT for neuroinflammation treatment approaches.
Manuscript submission demonstrating anti-inflammatory effects in a spinal cord injury rat model.
Presentation by Jacek M. Kwiecien, DVM, MSc, PhD, on a grain protein with anti-neuroinflammatory activity for better function in aging brain.
Patent granted in the United States for use of anti-inflammatory agents for treatment of inflammation after neurotrauma and related diseases.
USPTO Patent US20220395474A1 for treatment of inflammation in central nervous system diseases including the use of oral xanthohumol.
USPTO application regarding further treatment approaches.
International PCT for neuroinflammation treatment approaches.